Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;13(1):e1654.
doi: 10.1002/wnan.1654. Epub 2020 Jul 22.

Nanomedicine in lung cancer: Current states of overcoming drug resistance and improving cancer immunotherapy

Wei Wang  1 , Yuhao Hao  2 , Yusheng Liu  2 , Rui Li  2 , Da-Bing Huang  1 , Yue-Yin Pan  1
Affiliations
Review

Nanomedicine in lung cancer: Current states of overcoming drug resistance and improving cancer immunotherapy

Wei Wang et al. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Jan.

Abstract

Lung cancer is considered to cause the most cancer-related deaths worldwide. Due to the deficiency in early-stage diagnostics and local invasion or distant metastasis, the first line of treatment for most patients unsuitable for surgery is chemotherapy, targeted therapy or immunotherapy. Nanocarriers with the function of improving drug solubility, in vivo stability, drug distribution in the body, and sustained and targeted delivery, can effectively improve the effect of drug treatment and reduce toxic and side effects, and have been used in clinical treatment for lung cancer and many types of cancers. Here, we review nanoparticle (NP) formulation for lung cancer treatment including liposomes, polymers, and inorganic NPs via systemic and inhaled administration, and highlight the works of overcoming drug resistance and improving cancer immunotherapy. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.

Keywords: cancer immunotherapy; drug resistance; lung cancer; nanomedicine.

PubMed Disclaimer

References

REFERENCES

    1. Aqil, F., Munagala, R., Jeyabalan, J., Agrawal, A. K., Kyakulaga, A.-H., Wilcher, S. A., & Gupta, R. C. (2019). Milk exosomes-natural nanoparticles for siRNA delivery. Cancer Letters, 449, 186-195.
    1. Barenholz, Y. C. (2012). Doxil®-The first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release, 160(2), 117-134.
    1. Boulikas, T. (2004). Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncology Reports, 12(1), 3-12.
    1. Bourzac, K. (2014). Three known unknowns. Nature, 509(7502), S69-S71.
    1. Brown, J. M. (2002). Tumor microenvironment and the response to anticancer therapy. Cancer Biology & Therapy, 1(5), 453-458.

Publication types

LinkOut - more resources